TY - JOUR
T1 - A pilot study to evaluate a new combination therapy for gastric ulcer
T2 - Helicobacter pylori eradication therapy followed by gastroprotective treatment with rebamipide
AU - Terano, Akira
AU - Arakawa, Tetsuo
AU - Sugiyama, Toshiro
AU - Yoshikawa, Toshikazu
AU - Haruma, Ken
AU - Asaka, Masahiro
AU - Shimosegawa, Tooru
AU - Sakaki, Nobuhiro
AU - Ishii, Hiromasa
AU - Sakamoto, Choitsu
AU - Takahashi, Shin Ichi
AU - Kinoshita, Yoshikazu
AU - Fujioka, Toshio
AU - Kobayashi, Kenzo
PY - 2006/1
Y1 - 2006/1
N2 - Background and Aim: Controversies remain over the need for antiulcer treatment following 1-week eradication triple therapy for Helicobacter pylori-positive peptic ulcers. The usefulness of combination therapy for gastric ulcers in Japanese patients, which consists of H. pylori eradication followed by gastroprotective therapy with rebamipide, was therefore evaluated. Methods: The study was conducted in 52 H. pylori-positive patients with an endoscopically-proven open gastric ulcer. All patients received 1-week triple therapy (lansoprazole, amoxicillin and clarithromycin) followed by 7-week rebamipide therapy. After completion of the combination therapy, all patients underwent evaluation of ulcer healing by endoscopy, gastric ulcer symptoms and H. pylori eradication by rapid urease test and 13C-urea breath test. Results: The ulcer healing rates were 85.7% (36/42) at 8 weeks, 83.3% (30/36) in eradicated patients and 100% (6/6) in non-eradicated patients. The overall gastrointestinal symptom-free rate improved from 19.0% at baseline to 88.1% at 8 weeks. H. pylori was effectively eradicated in 85.7% (36/42) of patients. Conclusions: The results suggested that the combination therapy for open gastric ulcer was safe, well-tolerated and effective. However, data from a double-blind placebo-controlled study is necessary to confirm these findings.
AB - Background and Aim: Controversies remain over the need for antiulcer treatment following 1-week eradication triple therapy for Helicobacter pylori-positive peptic ulcers. The usefulness of combination therapy for gastric ulcers in Japanese patients, which consists of H. pylori eradication followed by gastroprotective therapy with rebamipide, was therefore evaluated. Methods: The study was conducted in 52 H. pylori-positive patients with an endoscopically-proven open gastric ulcer. All patients received 1-week triple therapy (lansoprazole, amoxicillin and clarithromycin) followed by 7-week rebamipide therapy. After completion of the combination therapy, all patients underwent evaluation of ulcer healing by endoscopy, gastric ulcer symptoms and H. pylori eradication by rapid urease test and 13C-urea breath test. Results: The ulcer healing rates were 85.7% (36/42) at 8 weeks, 83.3% (30/36) in eradicated patients and 100% (6/6) in non-eradicated patients. The overall gastrointestinal symptom-free rate improved from 19.0% at baseline to 88.1% at 8 weeks. H. pylori was effectively eradicated in 85.7% (36/42) of patients. Conclusions: The results suggested that the combination therapy for open gastric ulcer was safe, well-tolerated and effective. However, data from a double-blind placebo-controlled study is necessary to confirm these findings.
KW - Gastric ulcer
KW - Helicobacter pylori
KW - Pepsinogen
KW - Rebamipide
KW - Ulcer healing
UR - http://www.scopus.com/inward/record.url?scp=33645213007&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33645213007&partnerID=8YFLogxK
U2 - 10.1111/j.1440-1746.2005.04191.x
DO - 10.1111/j.1440-1746.2005.04191.x
M3 - Article
C2 - 16706820
AN - SCOPUS:33645213007
VL - 21
SP - 103
EP - 109
JO - Journal of Gastroenterology and Hepatology (Australia)
JF - Journal of Gastroenterology and Hepatology (Australia)
SN - 0815-9319
IS - 1 PART1
ER -